AR042705A1 - Derivados de pirazol modulador de ppar - Google Patents

Derivados de pirazol modulador de ppar

Info

Publication number
AR042705A1
AR042705A1 ARP040100011A ARP040100011A AR042705A1 AR 042705 A1 AR042705 A1 AR 042705A1 AR P040100011 A ARP040100011 A AR P040100011A AR P040100011 A ARP040100011 A AR P040100011A AR 042705 A1 AR042705 A1 AR 042705A1
Authority
AR
Argentina
Prior art keywords
pirazol
derivatives
ppar modulator
methyl
ppar
Prior art date
Application number
ARP040100011A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR042705A1 publication Critical patent/AR042705A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a un compuesto, ácido {2-metil-4-[3-metil-1-(4-trifluorometilfenil)-1H-pirazol-4-ilmetilsulfanil]fenoxi}acético. Composiciones farmacéuticas aceptables del mismo, procesos de obtención, y su uso en el tratamiento de diabetes, entre otras enfermedades.
ARP040100011A 2003-01-06 2004-01-05 Derivados de pirazol modulador de ppar AR042705A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43856303P 2003-01-06 2003-01-06

Publications (1)

Publication Number Publication Date
AR042705A1 true AR042705A1 (es) 2005-06-29

Family

ID=32713346

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100011A AR042705A1 (es) 2003-01-06 2004-01-05 Derivados de pirazol modulador de ppar

Country Status (8)

Country Link
US (2) US7396850B2 (es)
EP (2) EP1585733A1 (es)
AR (1) AR042705A1 (es)
AU (2) AU2003296404A1 (es)
CL (1) CL2004000011A1 (es)
PE (1) PE20041039A1 (es)
TW (1) TW200505867A (es)
WO (2) WO2004063165A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1585733A1 (en) * 2003-01-06 2005-10-19 Eli Lilly And Company Heterocyclic ppar modulators
RU2342365C2 (ru) * 2003-05-01 2008-12-27 Бристол-Маерс Сквибб Компани Арилзамещенные пиразоламиды в качестве ингибиторов киназ
MXPA06012093A (es) * 2004-04-28 2007-01-25 Hoffmann La Roche Derivados de fenilpirazol como activadores de receptores activadores del proliferador de peroxisoma (ppar).
EP1745003B1 (en) 2004-05-05 2010-10-27 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
JP4981662B2 (ja) 2004-05-05 2012-07-25 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規の化合物、その製法と使用
FR2882359A1 (fr) * 2005-02-24 2006-08-25 Negma Lerads Soc Par Actions S Derives activateurs de ppar, procede de preparation et application en therapeutique
CN101166720A (zh) * 2005-02-28 2008-04-23 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
EP1887000A4 (en) 2005-05-27 2011-09-07 Shionogi & Co ARYLACETATE DERIVATIVES WITH ISOXAZO EASY
ES2525217T3 (es) 2005-06-27 2014-12-19 Exelixis Patent Company Llc Moduladores de LXR basados en imidazol
ES2449618T3 (es) 2005-06-30 2014-03-20 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de PPAR-delta
CN101296914B (zh) 2005-08-26 2012-07-18 盐野义制药株式会社 具有ppar激动活性的衍生物
US20080249137A1 (en) * 2005-09-07 2008-10-09 Jack Lin PPAR active compounds
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
WO2007101864A2 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
AU2007239283B2 (en) 2006-04-18 2013-02-07 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor delta
WO2008010511A1 (en) * 2006-07-19 2008-01-24 Takeda Pharmaceutical Company Limited Screening method
WO2008073825A1 (en) * 2006-12-08 2008-06-19 Exelixis, Inc. Lxr and fxr modulators
US20100183696A1 (en) * 2007-01-30 2010-07-22 Allergan, Inc Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists
WO2008103574A2 (en) * 2007-02-23 2008-08-28 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US8263630B2 (en) * 2008-02-12 2012-09-11 Bristol-Myers Squibb Company 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type I inhibitors
LT2277874T (lt) 2008-04-15 2018-10-10 Nippon Chemiphar Co., Ltd. Peroksisomų proliferatoriaus aktyvuotų receptorių aktyvatorius
CN101643451B (zh) 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
CN103298469A (zh) 2010-08-31 2013-09-11 首尔大学校产学协力财团 PPARδ激动剂的胎儿重编程的用途
US9145369B2 (en) 2012-05-14 2015-09-29 Bayer Cropscience Ag Process for preparing 1-alkyl-3-fluoroalkyl-1H-pyrazole-4-carboxylic acid chlorides
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
EP3043789B1 (en) 2013-09-09 2020-07-08 vTv Therapeutics LLC Use of a ppar-delta agonists for treating muscle atrophy
BR112016016397B1 (pt) * 2014-01-24 2021-06-29 Bayer Cropscience Aktiengesellschaft Processo para preparar 1-alquil-3-difluorometil-5- fluoro-1h-pirazol-4-carbaldeídos ou os seus ésteres
TWI769182B (zh) 2016-10-05 2022-07-01 美商米突倍基公司 過氧化物酶體增生劑活化之受體（ppar）促效劑化合物之結晶及鹽形式
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0442448A3 (en) 1990-02-13 1992-08-12 Bristol-Myers Squibb Company Heterocyclic carboxylic acids and esters
JP3694774B2 (ja) 1997-10-31 2005-09-14 大鵬薬品工業株式会社 フェニルカルボン酸誘導体
ATE252091T1 (de) * 1999-08-27 2003-11-15 Lilly Co Eli Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
CO5221057A1 (es) * 2000-03-02 2002-11-28 Aventis Cropscience Sa Componentes y composiciones plagicidas
CZ20033328A3 (cs) 2001-06-07 2004-06-16 Eli Lilly And Company Modulátory receptorů aktivovaných proliferátory peroxisomů (PPAR)
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
WO2003099793A1 (en) * 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
EP1585733A1 (en) * 2003-01-06 2005-10-19 Eli Lilly And Company Heterocyclic ppar modulators

Also Published As

Publication number Publication date
US20060241157A1 (en) 2006-10-26
TW200505867A (en) 2005-02-16
AU2003296401A1 (en) 2004-08-10
WO2004063165A1 (en) 2004-07-29
WO2004063166A8 (en) 2005-03-03
PE20041039A1 (es) 2004-12-30
US7396850B2 (en) 2008-07-08
WO2004063166A1 (en) 2004-07-29
EP1585733A1 (en) 2005-10-19
US20070043220A1 (en) 2007-02-22
CL2004000011A1 (es) 2005-04-15
AU2003296404A1 (en) 2004-08-10
EP1583746A1 (en) 2005-10-12

Similar Documents

Publication Publication Date Title
AR042705A1 (es) Derivados de pirazol modulador de ppar
RS20070076A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
GT200400239A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
UY27878A1 (es) Derivados de indolinfenilsulfonamida
ATE486860T1 (de) Phenothiazin-derivat zur wundheilung
GT200500363A (es) 3-amino-pirazol [3,4b] piridinas con inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento.
EA200802208A1 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
IS7814A (is) Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
WO2009124266A3 (en) Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
CY1108992T1 (el) Η χρηση του υαλουρονικου οξεος για την παρασκευη συνθεσεων για τη θεραπευτικη αντιμετωπιση υποτροπιαζουσων αφθων της στοματικης κοιλοτητας
WO2005097135A3 (en) Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives
BRPI0517227B8 (pt) comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
MX2007004861A (es) Derivados de sulfonamida novedosos como moduladores de receptor glucocorticoide para el tratamiento de enfermedades inflamatorias.
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
UY27392A1 (es) Derivados del ácido indan acetico y su uso como agentes farmacéuticos, intermediarios, y método de preparación
NO20071798L (no) Dermalt pafore formuleringer for behandling av hudsykdommer i dyr
AR069508A1 (es) Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento
DK1727817T3 (da) Azabicyclooctan-3-onderivativer og anvendelse heraf
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
CR10092A (es) Nuevos derivados de furopirimidina aciclicos sustituidos y su uso
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине

Legal Events

Date Code Title Description
FB Suspension of granting procedure